Monitor the proxy statement/registration statement filing for details on expected redemptions and the final cash position. The $150M minimum cash condition is a key de-risking element. Watch for any competing SPAC proposals or shareholder litigation that could delay or alter the deal.
Price Chart
Executive Summary
TCGX Acquisition Corp. (TCGX) entered into a definitive business combination agreement to merge with TriGemX Bio, Inc. (formerly Kallyope, Inc.), a biotech company. The transaction is valued at a pre-money equity value of $361 million for TriGemX, with a concurrent $160 million PIPE financing at $10.00 per share. The combined entity will be named TriGemX Bio, Inc. and trade on Nasdaq under the ticker TGEM.
Key Financial Metrics
Key Facts
- TCGX Acquisition Corp. (SPAC) to merge with TriGemX Bio, Inc. (formerly Kallyope, Inc.) via a business combination agreement dated October 18, 2026.
- Pre-money equity value of TriGemX set at $361,000,000.
- Concurrent PIPE financing of $160,000,000 at $10.00 per share, anchored by TCG Crossover Fund III with a minimum commitment of $35,000,000.
- TCGX had approximately $86.7 million in its trust account as of the agreement date.
- Combined company to be named TriGemX Bio, Inc. and trade on Nasdaq under ticker TGEM.
- Closing condition requires Available Closing Cash to be at least $150,000,000.
- Sponsor forfeiture of up to 539,062 founder shares if Available Closing Cash is below $161,000,000.
- Post-closing board to consist of 7 directors, with 6 designated by TriGemX and 1 by TCGX.
- Lock-up agreements for sponsor, PIPE investors, and certain TriGemX stockholders.
- Registration rights agreement to be entered into at closing.
Financial Impact
Transaction values TriGemX at $361M pre-money. Combined entity will have access to ~$86.7M in trust plus $160M PIPE, subject to redemptions. Minimum closing cash condition of $150M provides a floor.
Risk Factors
- Shareholder redemptions could reduce available cash below the $150M minimum closing condition.
- Regulatory approvals and Nasdaq listing approval are required conditions.
- TriGemX is a pre-revenue biotech company; clinical and regulatory risks remain post-merger.
- Potential shareholder litigation could delay closing.
- Failure to obtain required shareholder approvals from both TCGX and TriGemX stockholders.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424754 |
| Document: d43527dex102.htm | 0001193125-26-424754 |
| Document: d43527dex104.htm | 0001193125-26-424754 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 425 | $10.01 $10.00 | ▼ −0.10% | ▼ −0.63% | $10.14 (+1.30%) |
Oct 19, 2026 7d ago | 425 | $10.01 $10.00 | ▼ −0.10% | ▼ −0.63% | $10.14 (+1.30%) |
Oct 19, 2026 7d ago | 425 | $10.02 $10.01 | ▼ −0.10% | ▼ −0.44% | $10.14 (+1.20%) |
Oct 19, 2026 7d ago | 8-K | $10.02 $10.01 | ▼ −0.10% | ▼ −0.44% | $10.14 (+1.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers